Contributor
Sophia Wen is an internal medicine resident at the University of Toronto.
In 2021, the FDA and EMA announced a new adverse event label for the use of intravenous (IV) iron in pregnancy. But the label is misleading and could worsen already inequitable access to an important treatment for iron deficiency in pregnancy.